Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia

Leukemia Research

Volumn 36, Issue 7, 2012, Pages 817-825

  Gater, Adam ^a   Heron, Louise ^a   Abetz Webb, Linda ^a   Coombs, John ^b   Simmons, Jeff ^b   Guilhot, François ^c   Rea, Delphine ^d  

^a ADELPHI REAL WORLD   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

Adherence; Chronic myeloid leukemia; Dasatinib; Imatinib; Nilotinib; Oral anticancer therapy; Tyrosine kinase inhibitor

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

CHRONIC MYELOID LEUKEMIA; CLINICAL COMPETENCE; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DOCTOR PATIENT RELATION; DRUG APPROVAL; DRUG DOSE COMPARISON; EVIDENCE BASED MEDICINE; FUNCTIONAL STATUS; HEALTH BEHAVIOR; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH PROMOTION; HUMAN; INTERPERSONAL COMMUNICATION; MEDICAL DECISION MAKING; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SATISFACTION; PEER REVIEW; PERSONALIZED MEDICINE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITATIVE RESEARCH; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SOCIAL ASPECT; STANDARDIZATION; SYSTEMATIC REVIEW; THEORETICAL MODEL; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEDICATION ADHERENCE; MODELS, BIOLOGICAL; PATIENT SATISFACTION; PROTEIN KINASE INHIBITORS;

EID: 84862316946     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.01.021     Document Type: Review

References (69)

1. Weingart S.N., Brown E., Bach P.B., Eng K., Johnson S.A., Kuzel T.M., et al. NCCN task force report: oral chemotherapy. JNCCN: J Natl Compr Canc Netw 2008, 6(Suppl. 3):S1-S14.
2. Halfdanarson T.R., Jatoi A. Oral cancer chemotherapy: the critical interplay between patient education and patient safety. Curr Oncol Rep 2010, 12(4):247-252.
3. Borner M.M., Schoffski P., de Wit R., Caponigro F., Comella G., Sulkes A., et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002, 38(February (3)):349-358.
4. Liu G., Franssen E., Fitch M.I., Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997, 15(January (1)):110-115.
5. Partridge A.H., Avorn J., Wang P.S., Winer E.P. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002, 94(May (9)):652-661.
6. Blasdel C., Bubalo J. Adherence to oral cancer therapies: meeting the challenge of new patient care needs. Special report 2006, McMahon Publishing Group, New York.
7. Ruddy K., Mayer E., Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009, 59(January (1)):56-66.
8. Sabate E. Adherence to long-term therapies: evidence for action (WHO); 2003 [PM:14562485].
9. Dimatteo M.R. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004, 42(March (3)):200-209.
10. Hohneker J., Shah-Mehta S., Brandt P.S. Perspectives on adherence and persistence with oral medications for cancer treatment. J Oncol Pract 2011, 7(January (1)):65-67.
11. Gleevec [package insert] 2009/2011, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
12. US Food and Drug Administration. Gleevec (imatinib mesylate), <>; 2001. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm110502.htm.
13. Wetzler M., Byrd J.C., Bloomfield C.D. Acute and chronic myeloid leukemia. Harrison's principles of internal medicine 2005, 631-641. McGraw-Hill Companies, Inc., New York. 16th ed. D.L. Kasper, E. Braunwald, A.S. Fauci, S.L. Hauser, D.L. Longo, J.L. Jameson (Eds.).
14. Deininger M., O'Brien S., Guilhot F., Goldman J., Hochhaus A., Hughes T., et al. International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Annual Meeting Abstracts 2009, 114:1126.
15. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355(December (23)):2408-2417.
16. Bixby D., Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011, 25(January (1)):7-22.
17. Jabbour E., Cortes J.E., Giles F.J., O'Brien S., Kantarjian H.M. Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007, 109(June (11)):2171-2181.
18. Tasigna [package insert] 2009/2011, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
19. Sprycel [package insert] 2009/2011, Bristol-Myers Squibb Company, Princeton, NJ.
20. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27(December (35)):6041-6051.
21. Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Ayala M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362(June (24)):2260-2270.
22. Kantarjian H.M., Giles F., Gattermann N., Bhalla K., Alimena G., Palandri F., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110(November (10)):3540-3546.
23. Wei G., Rafiyath S., Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 2010, 3. [Article number 47].
24. Cortes J.E., Egorin M.J., Guilhot F., Molimard M., Mahon F.X. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia [Review]. Leukemia 2009, 23(September (9)):1537-1544.
25. Picard S., Titier K., Etienne G., Teilhet E., Ducint D., Bernard M. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard dose imatinib in chronic myeloid leukaemia. Blood 2007, 109:3496-3499.
26. Breccia M., Efficace F., Alimena G. Imatinib treatment in chronic myelogenous leukemia: what have we learned so far? [Review]. Cancer Lett 2011, 300(January (2)):115-121.
27. Wu E.Q., Johnson S., Beaulieu N., Arana M., Bollu V., Guo A., et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010, 26(January (1)):61-69.
28. Wu E.Q., Guerin A., Yu A.P., Bollu V.K., Guo A., Griffin J.D. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin 2010, 26(12):2861-2869.
29. Noens L., Van Lierde M.-A., De Bock R., Verhoef G., Zachee P., Berneman Z., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113(22):5401-5411.
30. Marin D., Bazeos A., Mahon F.X., Eliasson L., Milojkovic D., Bua M., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28(May (14)):2381-2388.
31. Kiguchi T., Tauchi T., Ito Y., Miyazawa K., Kimura Y., Ohyashiki K. Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. Leuk Res 2009, 33(3):506-508.
32. Eliasson L., Clifford S., Barber N., Marin D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 2011, 35(May (5)):626-630.
33. Darkow T., Henk H.J., Thomas S.K., Feng W., Baladi J.F., Goldberg G.A., et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007, 25(6):481-496.
34. Ganesan P., Sagar T.G., Dubashi B., Rajendranath R., Kannan K., Cyriac S., et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 2011, 86(June (6)):471-474.
35. Abraham I., Noens L., De Bock R., Verhoef G., Zachee P., Berneman Z., et al. The variance in patient reported non adherence with imatinib treatment in chronic myeloid leukemia is attributable to both physicians and patients - results from the ADAGIO study. Haematologica 2008, 93:S1.
36. Almeida M.H., Pagnano K.B., Souza H., Miranda E.C.M., Souza C.D. High adherence to tyrosine kinase inhibitors seems to be related to best cytogenetic response in the Hasford lower risk group in chronic myeloid leukemia. ASH Annual Meeting Abstracts 2010, 116(December (21)):4477.
37. Almeida M.H., Pagnano K.B., Souza H., Souza C.D. Adherence to tyrosine kinase inhibitors (TK1) in chronic myeloid leukemia (CML) seems to be related to duration of treatment and type of TK1. Haematologica 2010, 95(Suppl. 2):343. [abs. 0820].
38. Bazeos A., Khorashad J., Mahon F.X., Eliasson L.L., Milojkovic D., Bua M., et al. Long term adherence to imatinib therapy is the critical factor for achieving molecular responses in chronic myeloid leukemia patients. ASH Annual Meeting Abstracts 2009, 114(December (22)):3290.
39. Doti C.A., Stemmelin G.R., Moiraghi E.B., Flores M.G., Garcia J., Murro H., et al. Adherence to imatinib mesylate treatment: two years follow up. ASH Annual Meeting Abstracts 2008, 112(December (11)):4267.
40. Feng W., Henk H., Thomas S., Baladi A., Hatfield G., Goldberg G., et al. Compliance and persistency with imatinib. J Clin Oncol 2006, 24(18S (June Suppl.)).
41. Fogliatto L., Capra M., Schaan M., Fassina K., Fernandes M.S., Schilling M.A., et al. Impact of comorbidity in event-free survival, toxicity and adherence to treatment in chronic myeloid leukemia patients treated with imatinib. ASH Annual Meeting Abstracts 2010, 116(December (21)):2296.
42. Guerin A., Bollu V., Guo A., Griffin J.D., Yu A.P., Wu E.Q. Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia. ASH Annual Meeting Abstracts 2010, 116(December (21)):3437.
43. Halpern R., Barghout V., Mody-Patel D., Williams D. Relationship between compliance, costs, hospitalizations for CML and GIST patients using imatinib mesylate. J Clin Oncol 2008, 26(20 (May Suppl.)).
44. Halpern R., Barghout V., Williams D. Compliance with imatinib mesylate associated with lower health resource utilization and costs for patients with CML and GIST. ASH Annual Meeting Abstracts 2007, 110(December (11)):5159.
45. Ibrahim A.R., Milojkovic D., Bua M., Khorshad J.S., Szydlo R., Eliasson L., et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for CML patients on long term imatinib therapy. ASH Annual Meeting Abstracts 2010, 116(December (21)):3414.
46. Johnson C., Cowan L., Gorospe G.L., Ailawadhi S. Disease knowledge in chronic myeloid leukemia (CML) patients as a predictor of compliance to treatment. ASH Annual Meeting Abstracts 2010, 116(December (21)):4481.
47. Noens L., van Lierde M.A., De Bock R., Verhoef G., Zachee P., Berneman Z., et al. Patient nonadherence and treatment response to imatinib in patients with chronic myeloid leukemia: results from the ADAGIO study. ASH Annual Meeting Abstracts 2008, 112(December (11)):2379.
48. St Charles M., Bollu V.K., Hornyak E., Coombs J., Blanchette C.M., DeAngelo D.J. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. ASH Annual Meeting Abstracts 2009, 114(December (22)):2209.
49. Tsang J., Rudychev S., Pescatore S. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). J Clin Oncol 2006, 24(18S (June Suppl.)).
50. van Lierde M.A., De Rop L., Serra F., Strobbe E., MacDonald K., Vancayzeele S., et al. Canonical correlation analysis (CCA) of imatinib treatment (ImRx) nonadherence (NA) with associated patient variables (APVs) in chronic myeloid leukemia (CML) - results from the ADAGIO study. ASH Annual Meeting Abstracts 2007, 110(December (11)):5164.
51. van Lierde M.A., De Rop L., Serra F., Strobbe E., MacDonald K., Vancayzeele S., et al. Multimethod clinical assessment of patterns and prevalence of nonadherence to imatinib treatment in patients with chronic myeloid leukemia: results from the ADAGIO study. ASH Annual Meeting Abstracts 2007, 110(11):5163.
52. Wu E.Q., Feng W., Johnson N., Beaulieu N., Cremieux P., Cortes J. Medical costs associated with imatinib (IM) non-compliance in chronic myeloid leukemia (CML) patients (pts). J Clin Oncol 2007, 25(18S (June Suppl.)).
53. Wu E.Q., Bollu V.K., Guo A., Guerin A., Yu A.P., Sirulnik A., et al. Non-adherence to imatinib in chronic myeloid leukemia patients is associated with a short term and long term negative impact on healthcare utilization and costs. ASH Annual Meeting Abstracts 2009, 114(December (22)):4270.
54. Yood M.U., Oliveria S.A., Hirji I., Cziraky M., Davis C. Adherence to treatment in patients with chronic myelogenous leukemia during a 10-year time period: a medical record review. ASH Annual Meeting Abstracts 2010, 116(21):1235.
55. Novartis Pharmaceuticals. Imatinib (Gleevec) prescribing information; 2011.
56. Marin D. Current status of imatinib as frontline therapy for chronic myeloid leukemia. Semin Hematol 2010, 47(4):312-318.
57. Kantarjian H.M., Talpaz M., O'Brien S., Jones D., Giles F., Garcia-Manero G., et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006, 108(September (6)):1835-1840.
58. Roethlisberger F.J., Dickson W.J. Management of the worker 1939, Harvard University Press, Cambridge, MA.
59. World Health Organization Adherence to long term therapies: evidence for action 2003.
60. Cramer J.A., Roy A., Burrell A., Fairchild C.J., Fuldeore M.J., Ollendorf D.A., et al. Medication compliance and persistence: terminology and definitions. Value Health 2008, 11(January (1)):44-47.
61. Engel G.L. The need for a new medical model: a challenge for biomedicine. Science 1977, 196(April (4286)):129-136.
62. McHorney C.A. The adherence estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin 2009, 25(January (1)):215-238.
63. Miller L.G., Liu H., Hays R.D., Golin C.E., Beck C.K., Asch S.M., et al. How well do clinicians estimate patients' adherence to combination antiretroviral therapy?. J Gen Intern Med 2002, 17(January (1)):1-11.
64. Zolnierek K.B., Dimatteo M.R. Physician communication and patient adherence to treatment: a meta-analysis. Med Care 2009, 47(August (8)):826-834.
65. Martin L.R., Dimatteo M.R., Lepper H.S. Facilitation of patient involvement in care: development and validation of a scale. Behav Med 2001, 27(3):111-120.
66. Ajzen I. The theory of planned behavior. Organ Behav Human Decis Process 1991, 50:179-211.
67. Bandura A. Social foundations of thought and action: a social cognitive theory 1986, Prentice-Hall Inc., Englewood Cliffs, NJ.
68. Becker M.H., Maiman L.A., Kirscht J.P., Haefner D.P., Drachman R.H. The health belief model and prediction of dietary compliance: a field experiment. J Health Soc Behav 1977, 18(December (4)):348-366.
69. Strathman A., Gleicher F., Boninger D.S., Edwards C.S. The consideration of future consequences: weighing immediate and distant outcomes of behavior. J Pers Social Psychology 1994, 66(4):742-752.